Startups, BioPharma

Tyrogenex raising $12M for wet AMD oral therapy

The reason Tyrogenex is using a compound for both wet AMD and cancer because both diseases, the company says, stem from the uncontrolled growth of blood cells.

X-82-VEGFR

Tyrogenex, a Florida biopharmaceutical company developing an oral medication for macular degeneration, is in the midst of a $12 million fundraise, according to a regulatory filing. It centers on increasing the potency, while mitigating the toxicity, of tyrosine kinase inhibitors.

The startup says its lead compound, X-82, is thought to target the basic mechanisms of neovascular eye disease.Working by inhibiting two growth factor receptors – VEGFR and PDGFR – the company’s testing X-82 in wet AMD, renal cell carcinoma, pancreatic neuroendocrine tumors and advanced solid tumors.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

The reason Tyrogenex is using a compound for both wet AMD and cancer because both diseases, the company says, stem from the uncontrolled growth of blood cells.

The wet AMD phase 2 trial is being held at 22 clinical sites in the U.S. and five in the U.K.

Topics